Bulletin
Investor Alert

Market Pulse Archives

Sept. 18, 2020, 7:42 a.m. EDT

Shares of Roche gain as it says arthritis drug can lessen need for ventilators in COVID-19 patients

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Roche Holding AG (ROG)
  • X
    Gilead Sciences Inc. (GILD)
  • X
    Eli Lilly & Co. (LLY)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Roche Holding AG /zigman2/quotes/206324342/delayed CH:ROG +0.29% gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than those receiving placebo. The Phase 3, randomized, double-blind, placebo-controlled study focused on enrolling minority patients with COVID-19-related pneumonia; there are 389 participants enrolled in the trial. However, the drug did not lead to a difference in mortality, Roche said. Roche is also testing Actemra with Gilead Sciences Inc.'s /zigman2/quotes/210293917/composite GILD -0.65% remdesivir, which is the only new drug to receive an emergency use authorization from the Food and Drug Administration as a COVID-19 treatment during the pandemic. Earlier this week Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY -1.58% and Incyte Corp. /zigman2/quotes/204510994/composite INCY -0.44% said their rheumatoid arthritis drug Olumiant when paired with remdesivir shortened recovery time for hospitalized coronavirus patients. Both findings, neither of which have been published yet in a peer-reviewed medical journal, for the first time in months point to a clinical benefit for rheumatoid arthritis drugs when treating some COVID-19 patients after a series of setbacks over the summer. Shares of Roche have gained 16.4% so far this year. Shares of Roche have gained 16.4% so far this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.21% is up 3.9%.

/zigman2/quotes/206324342/delayed
CH : Switzerland: SWX
CHF 294.75
+0.85 +0.29%
Volume: 1.89M
Oct. 30, 2020 5:31p
P/E Ratio
19.70
Dividend Yield
3.05%
Market Cap
CHF251.98 billion
Rev. per Employee
CHF601,914
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 58.15
-0.38 -0.65%
Volume: 11.87M
Oct. 30, 2020 4:00p
P/E Ratio
60.23
Dividend Yield
4.68%
Market Cap
$72.86 billion
Rev. per Employee
$1.89M
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 130.46
-2.09 -1.58%
Volume: 4.34M
Oct. 30, 2020 4:04p
P/E Ratio
21.36
Dividend Yield
2.27%
Market Cap
$124.80 billion
Rev. per Employee
$663,777
loading...
/zigman2/quotes/204510994/composite
US : U.S.: Nasdaq
$ 86.64
-0.38 -0.44%
Volume: 1.11M
Oct. 30, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$18.95 billion
Rev. per Employee
$1.38M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,269.96
-40.15 -1.21%
Volume: 3.01B
Oct. 30, 2020 5:18p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.